Moderna (MRNA) stock is spiraling Wednesday, down more than 8% at last check. Today's slide follows Tuesday's nearly 12% rally that was sparked by Monday's report from the Centers for Disease Control and Prevention (CDC) on the first death in the U.S. connected to the H5N1 bird flu.
The CDC said "the risk to the general public remains low" and that "no person-to-person transmission spread has been identified," but the news has caused volatility in Moderna's stock because it is developing a bird flu vaccine.
In July 2024, Moderna received $176 million from the U.S. Department of Health and Human Services to accelerate the development of its pandemic influenza vaccine, mRNA-1018.
Sign up for Kiplinger’s Free E-Newsletters
Profit and prosper with the best of expert advice on investing, taxes, retirement, personal finance and more - straight to your e-mail.
Profit and prosper with the best of expert advice - straight to your e-mail.
"This subtype of influenza virus causes a highly infectious, severe disease in birds called avian influenza and poses a risk for spillover into the human population," the company said in a statement. Moderna's mRNA pipeline tracker currently shows that vaccine is in Phase 3 studies.
As of January 6, the CDC noted that there have been 66 confirmed cases of the H5N1 bird flu in the United States since 2024, with only one other case occurring between 2022 and 2024.
Is Moderna stock a buy, sell or hold?
Moderna hit its all-time high back in 2021 when the healthcare stock was capitalizing on surging demand for its COVID-19 vaccine. Since its price peak near $484 in August of that year, shares have tumbled almost 90%. And Wall Street remains cautious on the drugmaker.
According to S&P Global Market Intelligence, the average analyst target price on the large-cap stock is $73.64, representing implied upside of about 70% to current levels. Despite the implied upside, the consensus recommendation is Hold.
Financial services firm Argus Research is one of those firms with a Hold rating on MRNA stock.
"We think that MRNA shares are appropriately valued at recent prices below $45," wrote Argus Research analyst Jasper Hellweg in a December 17 note. "We would consider an upgrade when the company is able to return to a period of earnings growth and when it has more of its product candidates approved and sold on the market."
Related Content
-
Exxon Mobil's Earnings Warning Shouldn't Worry InvestorsExxon Mobil said lower oil prices and refining margins will weigh on earnings, but Wall Street isn't overly concerned. Here's what you need to know.
-
Why Advanced Micro Devices Stock Was Double-DowngradedHSBC lowered its rating on Advanced Micro Devices stock amid several concerns including the chipmaker's ability to compete with Nvidia. Here's what to know.
-
Why Advanced Micro Devices Stock Was Double-Downgraded
HSBC lowered its rating on Advanced Micro Devices stock amid several concerns including the chipmaker's ability to compete with Nvidia. Here's what to know.
-
Stock Market Today: Stocks Dragged Down by Strong DataInvestors weigh the prospect of no more rate cuts in the current cycle.
-
Gold Investments Continue to ShineHere are some of the best reasons why you should include at least a little gold in your portfolio.
-
Nvidia CES 2025 Updates: What Investors Need to KnowNvidia stock is the worst Dow Jones stock Tuesday after the AI bellwether made several announcements at CES 2025. Here's what you need to know.
-
Meta Adds Dana White to Its Board, Ends Fact-Checking: What to KnowMeta stock is lower Tuesday after the Facebook parent said it is adding UFC CEO Dana White to its board of directors and ending fact-checking on its platforms.
-
Why McDonald's Is Still a Buy After Rolling Back DEI InitiativesMcDonald's stock is moving higher Tuesday after the fast food giant said it is scrapping certain DEI goals. Here's what you need to know.
-
Is Money Messing Up Your Family's Life?Parents who discuss money and attitudes toward money with their children are more likely to raise financially successful and responsible adults.
-
Do You Know the Power of Whole Life Insurance in Retirement?Worried about legacy planning, market volatility or where to get cash to cover surprise medical or home repair bills? This little-known tool could help.
